ライフサイエンスコーパス: metastatic phenotype

1 ly serves as a multivariate predictor of the metastatic phenotype ().

2 ses, including cancer stem cell survival and metastatic phenotype.

3 ay a specific role in the development of the metastatic phenotype.

4 romotes a transition to a more malignant and metastatic phenotype.

5 ding matrix, indicative of a transformed and metastatic phenotype.

6 n 4T1 cells conveys in vitro correlates of a metastatic phenotype.

7 vely lost as the cells take on a more highly metastatic phenotype.

8 s, promotes and contributes to IBC's extreme metastatic phenotype.

9 cells and the ECM molecule FN to promote the metastatic phenotype.

10 tegrin alphavbeta3 that is associated with a metastatic phenotype.

11 that loss of TBR2 leads to acquisition of a metastatic phenotype.

12 for further investigation in the context of metastatic phenotype.

13 differential gene expression regulating the metastatic phenotype.

14 nes differentially expressed with respect to metastatic phenotype.

15 was demonstrated between Fas expression and metastatic phenotype.

16 s can play important functional roles in the metastatic phenotype.

17 ression is the transition to an invasive and metastatic phenotype.

18 te angiogenesis are integral features of the metastatic phenotype.

19 thway contributes distinct properties to the metastatic phenotype.

20 ntially with Adriamycin and FUdR expressed a metastatic phenotype.

21 egulate hAR is, in part, responsible for the metastatic phenotype.

22 by facilitating growth or acquisition of the metastatic phenotype.

23 differentiation and partially reversing the metastatic phenotype.

24 have an influence on the development of the metastatic phenotype.

25 ich Met activity contributes to the invasive/metastatic phenotype.

26 ession that correlates with progression to a metastatic phenotype.

27 ole in the development and regulation of the metastatic phenotype.

28 sts that primary tissue is predictive of the metastatic phenotype.

29 and demonstrate their ability to induce the metastatic phenotype.

30 of FasL (95%), suggesting association with a metastatic phenotype.

31 velopment of melanoma and acquisition of the metastatic phenotype.

32 estrogen receptor (ER) negative, and highly metastatic phenotype.

33 oteases and angiogenic factors, and a highly metastatic phenotype.

34 aments alone is not sufficient to confer the metastatic phenotype.

35 with the progression of a primary tumor to a metastatic phenotype.

36 y to regulate an undifferentiated and highly metastatic phenotype.

37 re cell motility closely correlates with the metastatic phenotype.

38 and seem to be a feature of the aggressive, metastatic phenotype.

39 growth factor receptor)-positive, and highly metastatic phenotype.

40 actor SOX9, that promote proliferation and a metastatic phenotype.

41 umoral heterogeneity in the development of a metastatic phenotype.

42 Variable exon usage is associated with metastatic phenotype.

43 noma (HCC) fostering a highly aggressive and metastatic phenotype.

44 and diagnostic indicators of the aggressive, metastatic phenotype.

45 aling cascades that drive the MDA-9-mediated metastatic phenotype.

46 AC), a cancer type characterized by a highly metastatic phenotype.

47 but also cell signaling, which promotes the metastatic phenotype.

48 patient samples directly correlates with the metastatic phenotype.

49 sformed NIH 3T3 cells and led to an enhanced metastatic phenotype.

50 n of cancer stem cells, and acquisition of a metastatic phenotype.

51 n mutants of p110alpha produce a more severe metastatic phenotype.

52 secondary sites, reproducing the LgyLRV1(+) metastatic phenotype.

53 lls have an increased invasive but decreased metastatic phenotype.

54 than p53 mutant mice and a gain-of-function metastatic phenotype.

55 the tissue repair function to enhance their metastatic phenotype.

56 to Myc tumors associated with the increased metastatic phenotype.

57 eutic and radiation resistance, and even the metastatic phenotype.

58 evade apoptotic cell death and to acquire a metastatic phenotype.

59 Maspin transcription, thereby promoting the metastatic phenotype.

60 may provide a new approach to targeting the metastatic phenotype.

61 progression, with the goal of reversing the metastatic phenotype.

62 in rescued expression of KiSS-1 and reduced metastatic phenotype.

63 f which may undergo a reprogramming of their metastatic phenotype.

64 an important role in the development of the metastatic phenotype.

65 with a drug-resistant, highly invasive, and metastatic phenotype.

66 eregulate adhesion signaling and mediate the metastatic phenotype.

67 cell lines (M-4A4 and NM-2C5) with opposite metastatic phenotypes.

68 are often associated with more invasive and metastatic phenotypes.

69 ticularly in the development of invasive and metastatic phenotypes.

70 icated in the acquisition of tumorigenic and metastatic phenotypes.

71 een low canonical AR output and SRC-promoted metastatic phenotypes.

72 our study examines the genetic evolution of metastatic phenotypes.

73 nce that Slug enhances both tumor growth and metastatic phenotypes.

74 ependent activation of genes associated with metastatic phenotypes.

75 rogram and suppressed their self renewal and metastatic phenotypes.

76 ases (PTPases) associated with oncogenic and metastatic phenotypes.

77 hatases that are implicated in oncogenic and metastatic phenotypes.

78 their ability to cause motile, invasive and metastatic phenotypes.

79 nsufficient for, acquisition of a detectable metastatic phenotype; 2) demonstrated that metastatic su

80 astoma (NB) cells from a metastatic to a non-metastatic phenotype, a previously unknown function for

81 ne expression signature that correlated with metastatic phenotype and highlighted several GTPase sign

82 on of the human melanocyte towards the brain-metastatic phenotype and that NT enhance the activity of

83 These results suggest that the bone-specific metastatic phenotypes and gene expression signature iden

84 (NSCLC) expresses a particularly aggressive metastatic phenotype, and patients with this disease hav

85 network and the acquisition of the invasive-metastatic phenotype, and we show here that HGF/SF-Met s

86 n mitotically active cells that promoted pro-metastatic phenotypes, and in advanced PCa proved to be

87 Estrogen independence and progression to a metastatic phenotype are hallmarks of therapeutic resist

88 the DNA base and backbone structures of the metastatic phenotype are indistinguishable from those of

89 possible molecular mechanism for the highly metastatic phenotype associated with MCC.

90 egy to treat cancer by blocking invasive and metastatic phenotypes associated with EMT.

91 e derived from the mouse model abrogates the metastatic phenotype but does not affect tumor growth.

92 n breast cancer cells with a highly invasive/metastatic phenotype but not in poorly invasive/nonmetas

93 wn-regulation of Fas was associated with the metastatic phenotype, but alterations in Fas expression

94 protein 2 (AGR2) has been associated with a metastatic phenotype, but its mechanism of action and co

95 Acquisition of a metastatic phenotype by breast cancer cells includes alt

96 ortant implications for the acquisition of a metastatic phenotype by breast cancer cells.

97 may become altered during acquisition of the metastatic phenotype by cancer cells.

98 g in concert accelerate the acquisition of a metastatic phenotype by prostate tumor cells.

99 cancer cells to hypoxia, which promotes the metastatic phenotype by reducing intercellular adhesion

100 s ever to successfully transfer the complete metastatic phenotype by somatic cell fusion and support

101 nse is a critical step in the acquisition of metastatic phenotype by tumor cells.

102 rodent gene mediating tumor progression and metastatic phenotypes, can be used to drive imaging repo

103 ll-length MUC1 displayed a less invasive and metastatic phenotype compared with control-transfected c

104 ree derivative human lines with increasingly metastatic phenotypes, designated FL1, FL2, and FL3, wer

105 igh fat intake promotes the emergence of the metastatic phenotype; further research is required to es

106 rrent databases) that may also impact on the metastatic phenotype have also been identified.

107 protein, S100A4, have been shown to cause a metastatic phenotype in at least three independent model

108 ts variant cell line (1205-LU), selected for metastatic phenotype in athymic mice.

109 hanisms that underlie the development of the metastatic phenotype in breast cancer cells.

110 sion is also significantly correlated to the metastatic phenotype in breast tumor samples.

111 nd colon and bladder carcinomas and with the metastatic phenotype in carcinomas of the lung, breast,

112 ibit Snail expression and, consequently, the metastatic phenotype in DU-145 prostate cancer cells.

113 nonical NFkappaB pathway promotes a dormant, metastatic phenotype in ER(+) breast cancer and implicat

114 sion of stem/basal-like cells and a dormant, metastatic phenotype in ER(+) breast cancer cells.

115 Thrombin-treated tumor cells induce a metastatic phenotype in experimental pulmonary murine me

116 roblast development and the acquisition of a metastatic phenotype in genetically engineered mice with

117 expression of PSAP was able to suppress the metastatic phenotype in highly metastatic 4T1 and MDA-MB

118 s corresponds to lymphangitic carcinomatosis metastatic phenotype in human cancer patients, an extrem

119 y correlated with an apoptotic-resistant and metastatic phenotype in human colon carcinoma cell lines

120 a role for beta4 integrin expression in the metastatic phenotype in human osteosarcoma cells.

121 evels of S100A4 have been shown to produce a metastatic phenotype in independent models of breast can

122 mplete dominance of its undifferentiated and metastatic phenotype in multiple somatic cell hybridizat

123 ritical to conferring an ICAM-2-mediated non-metastatic phenotype in NB cells.

124 ther the effect of LPA on acquisition of the metastatic phenotype in ovarian cancer cells is mediated

125 as been implicated in the acquisition of the metastatic phenotype in several types of cancer.

126 ntegrin was sufficient to revert this highly metastatic phenotype in the MNNG-HOS model without signi

127 Alterations associated with the metastatic phenotype in the primary tumors include incre

128 benign cell tine is sufficient to produce a metastatic phenotype in this particular rat mammary mode

129 poptotic resistance is often associated with metastatic phenotype in tumor cells and is considered a

130 ase that is most closely associated with the metastatic phenotype in vitro and in vivo.

131 and silencing of these genes attenuated the metastatic phenotype in vitro and lung colonization in v

132 ctivity in vitro and adopted an invasive and metastatic phenotype in vivo, inferring significance of

133 static ccRCC cells reversed the invasive and metastatic phenotype in vivo.

134 r their abilities to mediate tumorigenic and metastatic phenotypes in athymic nude mice when expresse

135 y Sirtuin factor SIRT7 as a key regulator of metastatic phenotypes in both epithelial and mesenchymal

136 or GPCR signaling, strongly correlates with metastatic phenotypes in both prostate cancer cell lines

137 d with human cancer and with neo-plastic and metastatic phenotypes in model systems.

138 its involving LEDGF/p75 and AKT that promote metastatic phenotypes in this setting.

139 s for CADM1, SPHK1, and YAP/TAZ in mediating metastatic phenotypes in vitro and in vivo Notably, phar

140 ession contributes to several aspects of the metastatic phenotype including survival in the anchorage

141 ar activities capable of contributing to the metastatic phenotype, including growth, motility, invasi

142 re, CD44s may be a critical component of the metastatic phenotype induced by specific oncogenes.

143 MM activity was sufficient and necessary for metastatic phenotypes induced by RB loss in prostate can

144 rated that the transition of melanoma to the metastatic phenotype is associated with a loss of expres

145 hat the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 exp

146 Tumor progression to the metastatic phenotype is mainly dependent on tumor cell i

147 The metastatic phenotype is potentially an early predictor o

148 ortant early event in the development of the metastatic phenotype is the induction of genes that prom

149 integral membrane mucin associated with the metastatic phenotype, is overexpressed by most human car

150 essed the growth of Lewis lung carcinoma-low metastatic phenotype metastases in C57BL/6 mice by great

151 p53 is responsible for the gain-of-function metastatic phenotype observed in the mouse.

152 demonstrate a strong correlation between the metastatic phenotype of a cell and its IL-8 expression,

153 highly relevant to human cancer and that the metastatic phenotype of a tumor may be affected by the g

154 tor (EGF) receptor (EGFR) indicates a highly metastatic phenotype of breast cancer.

155 cadherin is associated with the invasive and metastatic phenotype of carcinomas.

156 t overexpression of Tiam1 contributes to the metastatic phenotype of colon cancer cells.

157 Met-Stat3 signaling pathway and explains the metastatic phenotype of FasL-expressing tumors.

158 of mechanisms that impede the aggressive and metastatic phenotype of human basal triple-negative-type

159 an important role in the acquisition of the metastatic phenotype of human melanoma cells.

160 ole in tumor invasion and contributes to the metastatic phenotype of human melanoma.

161 eptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the exp

162 The tumorigenic and metastatic phenotype of melanoma cells often correlates

163 ession in PAR1-silenced cells fully restores metastatic phenotype of melanoma, indicating that PAFR p

164 may be relevant to the hormone-insensitive, metastatic phenotype of most advanced adenocarcinomas of

165 in B has been implicated in the invasive and metastatic phenotype of numerous types of cancer.

166 ll outline biochemical events underlying the metastatic phenotype of ovarian cancer.

167 Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma

168 GLI1 are likely to contribute to the highly metastatic phenotype of PDAC.

169 such as TSPAN12, that could mediate the anti-metastatic phenotype of the ATF.

170 In vivo data further validated the metastatic phenotype of the in vitro model.

171 ancer and contributes to the tumorigenic and metastatic phenotypes of cancer cells.

172 ve function of cadherins and correlates with metastatic phenotypes of several cancers.

173 In this study, we compared the metastatic phenotypes of the parental MDA-MB-435 cells a

174 Overexpression of ROCK confers a metastatic phenotype on the nonmetastatic MCF-7 cell lin

175 ng how ezrin is involved in the invasive and metastatic phenotype remain unclear.

176 1/CREB contributes to the acquisition of the metastatic phenotype remains unclear.

177 itro model which displayed the signatures of metastatic phenotype such as migration, invasiveness, ch

178 imus do not appear to have a more aggressive metastatic phenotype than those whose disease progresses

179 cells can exhibit a platelet-interactive and metastatic phenotype that is controlled by the activatio

180 on by tumor cells has been associated with a metastatic phenotype, the nature of the cellular target

181 tify the genes associated with the most lung-metastatic phenotype, the RNA complement from the parent

182 led miRNAs as suppressors of cell-autonomous metastatic phenotypes, the roles of non-coding RNAs in n

183 te bone marrow progenitor cells toward a pro-metastatic phenotype through MET" by Peinado and colleag

184 onsible for inducing specific aspects of the metastatic phenotype to allow for improved clinical dete

185 ized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells.

186 ion alone confers a transformed and in vitro metastatic phenotype to otherwise normal MCF-12A cells.

187 e growth of primary Lewis lung carcinoma-low metastatic phenotype tumors.

188 The metastatic phenotype typically is characterized by augme

189 ma and contributes to the acquisition of the metastatic phenotype via upregulation of PAR-1.

190 hanism of NPI-0052-induced inhibition of the metastatic phenotype was corroborated by: (1) treatment

191 in the progression of melanoma to the brain-metastatic phenotype, we determined whether NT stimulate

192 -function is critical for acquisition of the metastatic phenotype, we have compared the ability of Fa

193 To explore the mutant p53 metastatic phenotype, we used expression arrays to compa

194 that may be responsible for the invasive and metastatic phenotype, we used spectral karyotyping (SKY)

195 Altered metastatic phenotypes were not derivative of primary tum

196 downregulation recapitulated miR-194-driven metastatic phenotypes, whereas overexpression of a nonta

197 rates with H-RAS to induce an aggressive and metastatic phenotype with the unusual occurrence of brai